APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

Selected research

Market Analysis & Forecast

Global GLP-1 Drug Market Analysis and Forecast 2026-2032

21 December 2025197 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Glucagon-like peptide-1 (GLP-1) drugs are peptide therapeutics that mimic or potentiate the actions of endogenous GLP-1 at the GLP-1 receptor, a class-B G-protein–coupled receptor expressed on pancreatic islet cells, in the gastrointestinal tract, and in the central and cardiovascular systems. Pharmacologically they restore or amplify the physiologic “incretin effect”: in hyperglycaemic states they enhance glucose-dependent insulin secretion from β-cells, suppress inappropriate glucagon from α-cells, slow gastric emptying early in treatment, and reduce appetite via hypothalamic and brainstem pathways. Because their insulinotropic action is glucose-dependent, GLP-1 receptor agonists (GLP-1RAs) have a low intrinsic risk of hypoglycaemia unless combined with insulin or insulin secretagogues, while their gastrointestinal effects (nausea, vomiting, diarrhoea) are class-typical, dose-related and mitigated by stepwise titration.

At the molecular level the class spans two lineages. Exendin-based agents (e.g., exenatide and lixisenatide) derive from exendin-4 and are naturally DPP-4–resistant. Human-sequence analogues (e.g., liraglutide, semaglutide) and fusion constructs (e.g., dulaglutide) introduce substitutions or conjugations that protect the peptide from dipeptidyl peptidase-4 and renal clearance and, in long-acting variants, promote albumin binding or extend half-life through Fc fusion or PEGylation. Liraglutide carries a C16 fatty-acid side chain to bind albumin; semaglutide combines a DPP-4–resistant substitution with a C18 fatty-acid–spacer for strong albumin binding; dulaglutide fuses two GLP-1 analog moieties to a modified IgG4 Fc to slow elimination; exenatide extended-release incorporates the peptide into PLGA microspheres for weekly release; oral semaglutide employs the absorption enhancer SNAC to enable gastric uptake of an otherwise parenteral peptide. These structural strategies drive pharmacokinetics and clinical phenotype: short-exposure agents exert a proportionally larger post-prandial effect (via gastric emptying), while sustained-exposure agents have stronger fasting-glucose effects and smoother 24-hour control.

For clarity in product mapping, the marketed GLP-1RA portfolio covers human-sequence and exendin-based APIs across daily, weekly and oral modalities. Representative single-agent brands include exenatide immediate-release (Byetta) and extended-release (Bydureon/BCise), lixisenatide (Adlyxin/Lyxumia), liraglutide daily injection for diabetes (Victoza) and for weight management (Saxenda), dulaglutide weekly injection (Trulicity), semaglutide weekly injection for diabetes (Ozempic) and for weight management and cardiovascular risk reduction in appropriate populations (Wegovy), and semaglutide oral tablets (Rybelsus). Fixed-ratio combinations pair a GLP-1RA with basal insulin—insulin degludec + liraglutide (IDegLira; Xultophy) and insulin glargine + lixisenatide (iGlarLixi; Soliqua/Suliqua)—to streamline intensification in type 2 diabetes. Regional markets also include China domestic GLP-1RAs such as beinaglutide (short-acting, human-sequence GLP-1[7-36]) and PEG-loxenatide (weekly PEGylated exendin analogue). Dual- or multi-receptor incretin agonists exist but, by definition, sit outside the “GLP-1-only” class.

Read the full market overview

Indications in routine practice cluster into three labeled application domains. In type 2 diabetes (T2D), GLP-1RAs are used as an adjunct to diet and exercise as monotherapy when metformin is inappropriate, or in combination with oral agents and/or insulin when additional glycaemic control is needed; some agents have paediatric T2D labeling. In chronic weight management (Obesity), higher-dose liraglutide and semaglutide carry indications for adults with obesity or overweight with weight-related comorbidities, and certain labels extend to adolescents. In cardiovascular risk reduction (CV risk), specific products are approved to reduce major adverse cardiovascular events in adults with T2D and established atherosclerotic cardiovascular disease, and selected high-dose semaglutide carries a cardiovascular-risk reduction label in adults with established CVD who are overweight or obese. Risk-reduction labeling in chronic kidney disease for T2D populations is best treated as a T2D sub-label rather than a separate application domain. These labeled uses are product-specific; they should not be generalized across the entire class without reference to the individual label.

Mechanistically, receptor activation increases intracellular cAMP and engages PKA and Epac2 pathways, amplifying the β-cell exocytotic response to glucose, modulating β-cell gene expression and survival signals, and repressing α-cell glucagon in hyperglycaemia. In the gut, vagal and local effects slow gastric emptying at treatment initiation, which blunts post-prandial glucose excursions; this effect often attenuates with chronic dosing for long-acting agents. In the CNS, activation of POMC/CART neurons and downstream circuits decreases appetite and energy intake; peripheral effects on adipose tissue, liver and kidney contribute to weight loss and natriuresis. Cardiometabolic benefits observed in outcome studies likely reflect an integrated impact on weight, blood pressure, glycaemia, lipids and vascular inflammation rather than a single pathway.

Pharmacology and formulation determine dose cadence and “type.” In market segmentation, short-acting agents are those given daily or multiple times per day and are characterized by prominent post-prandial control; examples include exenatide immediate-release, lixisenatide and daily liraglutide. Long-acting agents deliver sustained exposure with weekly administration or, in the case of oral semaglutide, long pharmacodynamic activity despite daily dosing; examples include dulaglutide, semaglutide subcutaneous weekly, exenatide extended-release and PEG-loxenatide. Fixed-ratio combinations couple a GLP-1RA with basal insulin to produce complementary fasting and prandial control in a single daily injection. Oral semaglutide provides a non-injectable option but introduces administration rules—fasting state, limited water intake, and a wait period before food or other medications—that can affect real-world adherence.

Adherence is driven by device, titration and tolerability. Weekly autoinjectors lower injection burden and generally improve persistence compared with daily injectables, but gastrointestinal tolerability still requires careful uptitration. Oral semaglutide avoids needles yet trades that advantage for fasting-administration complexity; some patients prefer daily pens for simplicity once trained. Across the class, gradual dose escalation from a low introductory dose is central to minimizing GI symptoms. Most agents have low intrinsic hypoglycaemia risk when used without insulin or sulfonylureas; combination use often necessitates down-titration of the concomitant secretagogue or basal insulin as glycaemia improves. Class warnings include a contraindication in patients with personal or family history of medullary thyroid carcinoma or MEN2 for labels that carry a C-cell tumor warning, caution in patients with prior pancreatitis, and attention to gallbladder disease signals. Slowed gastric emptying can alter the absorption of co-administered oral drugs with a narrow therapeutic window, which warrants timing adjustments in practice. Rapid glycaemic improvement in susceptible patients may transiently worsen retinopathy and should be monitored.

From a development standpoint the class evolved from twice-daily exendin-based injections to weekly sustained-exposure analogues and, most recently, to high-dose weight-management regimens and an oral tablet formulation. Cardiovascular-outcomes programs transformed GLP-1RAs from pure glucose-lowering agents into cardiometabolic medicines with event-reduction labels for selected products and populations. Manufacturing has scaled from conventional peptide synthesis and sterile vialing to sophisticated autoinjector pens, PLGA microsphere encapsulation and tablet technologies that enable gastric uptake; these choices shape supply chains, dose flexibility and cost profiles.

In sum, GLP-1 drugs are a coherent but diverse class unified by a glucose-dependent incretin mechanism and differentiated by structure, exposure profile, dose form and label. The practical taxonomy that matters in clinical and market analysis is simple and serviceable: type by dosing profile (Short-acting; Long-acting; Fixed-ratio combo), modality by route (injection; oral), and application by labeled domain (T2D; Obesity; CV risk). Within that frame the choice of agent is a balance among glycaemic and weight targets, cardiovascular risk status, patient preference for frequency and route, and the operational realities of access, price and supply.

The global GLP-1 Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Asia-Pacific market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of GLP-1 Drug include Novo Nordisk, Eli Lilly, Sanofi, Teva, Jiangsu Hansoh Pharmaceutical, Huadong Medicine, Benemae Pharmaceutical, Tonghua Dongbao Pharma and Chia Tai-Tianqing Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for GLP-1 Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of GLP-1 Drug, also provides the sales of main regions and countries. Of the upcoming market potential for GLP-1 Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GLP-1 Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global GLP-1 Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for GLP-1 Drug sales, projected growth trends, production technology, application and end-user industry.

GLP-1 Drug Segment by Company

Novo Nordisk

Eli Lilly

Sanofi

Teva

Jiangsu Hansoh Pharmaceutical

Huadong Medicine

Benemae Pharmaceutical

Tonghua Dongbao Pharma

Chia Tai-Tianqing Pharmaceutical

AstraZeneca

GLP-1 Drug Segment by Type

Short-acting

Long-acting

GLP-1 Drug Segment by Indications

T2D

CV risk

Obesity

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of GLP-1 Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global GLP-1 Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Short-acting Major Manufacturers Table 3. Long-acting Major Manufacturers Table 4. Global GLP-1 Drug Market Size Growth Rate by Indications (US$ Million), 2021 VS 2025 VS 2032 Table 5. T2D Major Manufacturers Table 6. CV risk Major Manufacturers Table 7. Obesity Major Manufacturers Table 8. GLP-1 Drug Industry Trends Table 9. GLP-1 Drug Industry Drivers Table 10. GLP-1 Drug Industry Opportunities and Challenges Table 11. GLP-1 Drug Industry Restraints Table 12. Global GLP-1 Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global GLP-1 Drug Revenue by Region (2021-2026) & (US$ Million) Table 14. Global GLP-1 Drug Revenue by Region (2027-2032) & (US$ Million) Table 15. Global GLP-1 Drug Revenue Market Share by Region (2021-2026) Table 16. Global GLP-1 Drug Revenue Market Share by Region (2027-2032) Table 17. Global GLP-1 Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 18. Global GLP-1 Drug Sales by Region (2021-2026) & (Sales (k PMT)) Table 19. Global GLP-1 Drug Sales by Region (2027-2032) & (Sales (k PMT)) Table 20. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 21. Global GLP-1 Drug Sales Market Share by Region (2027-2032) Table 22. Global GLP-1 Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global GLP-1 Drug Revenue Market Share by Manufacturers (2021-2026) Table 24. Global GLP-1 Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global GLP-1 Drug Sales Market Share by Manufacturers (2021-2026) Table 26. Global GLP-1 Drug Sales Price (Net Price (USD/PMT)) of Manufacturers (2021-2026) Table 27. Global GLP-1 Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global GLP-1 Drug Manufacturers, Product Type & Application Table 30. Global GLP-1 Drug Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global GLP-1 Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global GLP-1 Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 35. Global GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 36. Global GLP-1 Drug Revenue Market Share by Type (2021-2026) Table 37. Global GLP-1 Drug Revenue Market Share by Type (2027-2032) Table 38. Global GLP-1 Drug Sales by Type 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 39. Global GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 40. Global GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 41. Global GLP-1 Drug Sales Market Share by Type (2021-2026) Table 42. Global GLP-1 Drug Sales Market Share by Type (2027-2032) Table 43. Global GLP-1 Drug Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 44. Global GLP-1 Drug Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 45. Global GLP-1 Drug Revenue by Indications 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 47. Global GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 48. Global GLP-1 Drug Revenue Market Share by Indications (2021-2026) Table 49. Global GLP-1 Drug Revenue Market Share by Indications (2027-2032) Table 50. Global GLP-1 Drug Sales by Indications 2021 VS 2025 VS 2032 (Sales (k PMT)) Table 51. Global GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 52. Global GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 53. Global GLP-1 Drug Sales Market Share by Indications (2021-2026) Table 54. Global GLP-1 Drug Sales Market Share by Indications (2027-2032) Table 55. Global GLP-1 Drug Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 56. Global GLP-1 Drug Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 57. Novo Nordisk Company Information Table 58. Novo Nordisk Business Overview Table 59. Novo Nordisk GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 60. Novo Nordisk GLP-1 Drug Product Portfolio Table 61. Novo Nordisk Recent Development Table 62. Eli Lilly Company Information Table 63. Eli Lilly Business Overview Table 64. Eli Lilly GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 65. Eli Lilly GLP-1 Drug Product Portfolio Table 66. Eli Lilly Recent Development Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 70. Sanofi GLP-1 Drug Product Portfolio Table 71. Sanofi Recent Development Table 72. Teva Company Information Table 73. Teva Business Overview Table 74. Teva GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 75. Teva GLP-1 Drug Product Portfolio Table 76. Teva Recent Development Table 77. Jiangsu Hansoh Pharmaceutical Company Information Table 78. Jiangsu Hansoh Pharmaceutical Business Overview Table 79. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 80. Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio Table 81. Jiangsu Hansoh Pharmaceutical Recent Development Table 82. Huadong Medicine Company Information Table 83. Huadong Medicine Business Overview Table 84. Huadong Medicine GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 85. Huadong Medicine GLP-1 Drug Product Portfolio Table 86. Huadong Medicine Recent Development Table 87. Benemae Pharmaceutical Company Information Table 88. Benemae Pharmaceutical Business Overview Table 89. Benemae Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 90. Benemae Pharmaceutical GLP-1 Drug Product Portfolio Table 91. Benemae Pharmaceutical Recent Development Table 92. Tonghua Dongbao Pharma Company Information Table 93. Tonghua Dongbao Pharma Business Overview Table 94. Tonghua Dongbao Pharma GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 95. Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio Table 96. Tonghua Dongbao Pharma Recent Development Table 97. Chia Tai-Tianqing Pharmaceutical Company Information Table 98. Chia Tai-Tianqing Pharmaceutical Business Overview Table 99. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 100. Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio Table 101. Chia Tai-Tianqing Pharmaceutical Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca GLP-1 Drug Sales (Sales (k PMT)), Revenue (US$ Million), Price (Net Price (USD/PMT)) and Gross Margin (2021-2026) Table 105. AstraZeneca GLP-1 Drug Product Portfolio Table 106. AstraZeneca Recent Development Table 107. North America GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. North America GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. North America GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 110. North America GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 111. North America GLP-1 Drug Sales Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 112. North America GLP-1 Drug Sales Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 113. North America GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 114. North America GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 115. North America GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 116. North America GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 117. North America GLP-1 Drug Sales Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 118. North America GLP-1 Drug Sales Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 119. North America GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (Sales (k PMT)) Table 123. North America GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 124. North America GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 125. North America GLP-1 Drug Sales Price by Country (2021-2026) & (Net Price (USD/PMT)) Table 126. North America GLP-1 Drug Sales Price by Country (2027-2032) & (Net Price (USD/PMT)) Table 127. United States GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 128. Canada GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 129. Mexico GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 130. Europe GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 133. Europe GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 134. Europe GLP-1 Drug Sales Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 135. Europe GLP-1 Drug Sales Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 136. Europe GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 137. Europe GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 138. Europe GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 139. Europe GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 140. Europe GLP-1 Drug Sales Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 141. Europe GLP-1 Drug Sales Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 142. Europe GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (Sales (k PMT)) Table 146. Europe GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 147. Europe GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 148. Europe GLP-1 Drug Sales Price by Country (2021-2026) & (Net Price (USD/PMT)) Table 149. Europe GLP-1 Drug Sales Price by Country (2027-2032) & (Net Price (USD/PMT)) Table 150. Germany GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 151. France GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 152. U.K. GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 153. Italy GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 154. Russia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 155. Spain GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 156. Netherlands GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 157. Switzerland GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 158. Sweden GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 159. Poland GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 160. China GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 161. China GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 162. China GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 163. China GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 164. China GLP-1 Drug Sales Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 165. China GLP-1 Drug Sales Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 166. China GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 167. China GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 168. China GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 169. China GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 170. China GLP-1 Drug Sales Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 171. China GLP-1 Drug Sales Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 172. Asia GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 175. Asia GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 176. Asia GLP-1 Drug Sales Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 177. Asia GLP-1 Drug Sales Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 178. Asia GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 179. Asia GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 180. Asia GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 181. Asia GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 182. Asia GLP-1 Drug Sales Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 183. Asia GLP-1 Drug Sales Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 184. Asia GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (Sales (k PMT)) Table 188. Asia GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 189. Asia GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 190. Asia GLP-1 Drug Sales Price by Country (2021-2026) & (Net Price (USD/PMT)) Table 191. Asia GLP-1 Drug Sales Price by Country (2027-2032) & (Net Price (USD/PMT)) Table 192. Japan GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 193. South Korea GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 194. India GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 195. Australia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 196. Taiwan GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 198. SAMEA GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA GLP-1 Drug Sales by Type (2021-2026) & (Sales (k PMT)) Table 201. SAMEA GLP-1 Drug Sales by Type (2027-2032) & (Sales (k PMT)) Table 202. SAMEA GLP-1 Drug Sales Price by Type (2021-2026) & (Net Price (USD/PMT)) Table 203. SAMEA GLP-1 Drug Sales Price by Type (2027-2032) & (Net Price (USD/PMT)) Table 204. SAMEA GLP-1 Drug Revenue by Indications (2021-2026) & (US$ Million) Table 205. SAMEA GLP-1 Drug Revenue by Indications (2027-2032) & (US$ Million) Table 206. SAMEA GLP-1 Drug Sales by Indications (2021-2026) & (Sales (k PMT)) Table 207. SAMEA GLP-1 Drug Sales by Indications (2027-2032) & (Sales (k PMT)) Table 208. SAMEA GLP-1 Drug Sales Price by Indications (2021-2026) & (Net Price (USD/PMT)) Table 209. SAMEA GLP-1 Drug Sales Price by Indications (2027-2032) & (Net Price (USD/PMT)) Table 210. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (Sales (k PMT)) Table 214. SAMEA GLP-1 Drug Sales by Country (2021-2026) & (Sales (k PMT)) Table 215. SAMEA GLP-1 Drug Sales by Country (2027-2032) & (Sales (k PMT)) Table 216. SAMEA GLP-1 Drug Sales Price by Country (2021-2026) & (Net Price (USD/PMT)) Table 217. SAMEA GLP-1 Drug Sales Price by Country (2027-2032) & (Net Price (USD/PMT)) Table 218. Brazil GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 219. Argentina GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 220. Chile GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 221. Colombia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 222. Peru GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 224. Israel GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 225. UAE GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 226. Turkey GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 227. Iran GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 228. Egypt GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. GLP-1 Drug Distributors List Table 232. GLP-1 Drug Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. GLP-1 Drug Image Figure 2. Global GLP-1 Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Short-acting Image Figure 5. Long-acting Image Figure 6. Global GLP-1 Drug Market Size Growth Rate by Indications (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global GLP-1 Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. T2D Image Figure 9. CV risk Image Figure 10. Obesity Image Figure 11. Global GLP-1 Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 13. Global GLP-1 Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global GLP-1 Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global GLP-1 Drug Revenue Market Share by Region (2021-2032) Figure 16. Global GLP-1 Drug Sales (2021-2032) & (Sales (k PMT)) Figure 17. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (Sales (k PMT)) Figure 18. Global GLP-1 Drug Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico GLP-1 Drug Sales YoY (2021-2032) & (Sales (k PMT)) Figure 20. Europe GLP-1 Drug Sales YoY (2021-2032) & (Sales (k PMT)) Figure 21. China GLP-1 Drug Sales YoY (2021-2032) & (Sales (k PMT)) Figure 22. Asia (Excluding China) GLP-1 Drug Sales YoY (2021-2032) & (Sales (k PMT)) Figure 23. South America, Middle East and Africa GLP-1 Drug Sales YoY (2021-2032) & (Sales (k PMT)) Figure 24. Global GLP-1 Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global GLP-1 Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global GLP-1 Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global GLP-1 Drug Revenue Market Share by Type (2021-2032) Figure 30. Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 31. Global GLP-1 Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global GLP-1 Drug Sales Market Share by Type (2021-2032) Figure 33. Global GLP-1 Drug Revenue by Indications (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global GLP-1 Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global GLP-1 Drug Revenue Market Share by Indications (2021-2032) Figure 36. Global GLP-1 Drug Sales by Indications (2021 VS 2025 VS 2032) & (Sales (k PMT)) Figure 37. Global GLP-1 Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global GLP-1 Drug Sales Market Share by Indications (2021-2032) Figure 39. North America GLP-1 Drug Revenue Share by Type (2021-2032) Figure 40. North America GLP-1 Drug Sales Share by Type (2021-2032) Figure 41. North America GLP-1 Drug Revenue Share by Indications (2021-2032) Figure 42. North America GLP-1 Drug Sales Share by Indications (2021-2032) Figure 43. North America GLP-1 Drug Revenue Share by Country (2021-2032) Figure 44. North America GLP-1 Drug Sales Share by Country (2021-2032) Figure 45. Europe GLP-1 Drug Revenue Share by Type (2021-2032) Figure 46. Europe GLP-1 Drug Sales Share by Type (2021-2032) Figure 47. Europe GLP-1 Drug Revenue Share by Indications (2021-2032) Figure 48. Europe GLP-1 Drug Sales Share by Indications (2021-2032) Figure 49. Europe GLP-1 Drug Revenue Share by Country (2021-2032) Figure 50. Europe GLP-1 Drug Sales Share by Country (2021-2032) Figure 51. China GLP-1 Drug Revenue Share by Type (2021-2032) Figure 52. China GLP-1 Drug Sales Share by Type (2021-2032) Figure 53. China GLP-1 Drug Revenue Share by Indications (2021-2032) Figure 54. China GLP-1 Drug Sales Share by Indications (2021-2032) Figure 55. Asia GLP-1 Drug Revenue Share by Type (2021-2032) Figure 56. Asia GLP-1 Drug Sales Share by Type (2021-2032) Figure 57. Asia GLP-1 Drug Revenue Share by Indications (2021-2032) Figure 58. Asia GLP-1 Drug Sales Share by Indications (2021-2032) Figure 59. Asia GLP-1 Drug Revenue Share by Country (2021-2032) Figure 60. Asia GLP-1 Drug Sales Share by Country (2021-2032) Figure 61. SAMEA GLP-1 Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA GLP-1 Drug Sales Share by Type (2021-2032) Figure 63. SAMEA GLP-1 Drug Revenue Share by Indications (2021-2032) Figure 64. SAMEA GLP-1 Drug Sales Share by Indications (2021-2032) Figure 65. SAMEA GLP-1 Drug Revenue Share by Country (2021-2032) Figure 66. SAMEA GLP-1 Drug Sales Share by Country (2021-2032) Figure 67. GLP-1 Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. GLP-1 Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting
  • Long-acting
Applications
  • T2D
  • CV risk
  • Obesity
Companies covered
  • Novo Nordisk
  • Eli Lilly
  • Sanofi
  • Teva
  • Jiangsu Hansoh Pharmaceutical
  • Huadong Medicine
  • Benemae Pharmaceutical
  • Tonghua Dongbao Pharma
  • Chia Tai-Tianqing Pharmaceutical
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 GLP-1 Drug Market by Type
  3. 1.2.1 Global GLP-1 Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Short-acting
  5. 1.2.3 Long-acting
  6. 1.3 GLP-1 Drug Market by Indications
  7. 1.3.1 Global GLP-1 Drug Market Size by Indications, 2021 VS 2025 VS 2032
  8. 1.3.2 T2D
  9. 1.3.3 CV risk
  10. 1.3.4 Obesity
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 GLP-1 Drug Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global GLP-1 Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global GLP-1 Drug Revenue by Region
  3. 3.2.1 Global GLP-1 Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global GLP-1 Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global GLP-1 Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global GLP-1 Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global GLP-1 Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global GLP-1 Drug Sales by Region
  9. 3.4.1 Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global GLP-1 Drug Sales by Region (2021-2026)
  11. 3.4.3 Global GLP-1 Drug Sales by Region (2027-2032)
  12. 3.4.4 Global GLP-1 Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global GLP-1 Drug Revenue by Manufacturers
  2. 4.1.1 Global GLP-1 Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global GLP-1 Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global GLP-1 Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global GLP-1 Drug Sales by Manufacturers
  6. 4.2.1 Global GLP-1 Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global GLP-1 Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global GLP-1 Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global GLP-1 Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global GLP-1 Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global GLP-1 Drug Manufacturers, Product Type & Application
  13. 4.7 Global GLP-1 Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global GLP-1 Drug Market CR5 and HHI
  16. 4.8.2 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3
5 GLP-1 Drug Market by Type
  1. 5.1 Global GLP-1 Drug Revenue by Type
  2. 5.1.1 Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global GLP-1 Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global GLP-1 Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global GLP-1 Drug Sales by Type
  6. 5.2.1 Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Drug Sales by Type (2021-2032) & (Sales (k PMT))
  8. 5.2.3 Global GLP-1 Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global GLP-1 Drug Price by Type
6 GLP-1 Drug Market by Application
  1. 6.1 Global GLP-1 Drug Revenue by Application
  2. 6.1.1 Global GLP-1 Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global GLP-1 Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global GLP-1 Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global GLP-1 Drug Sales by Application
  6. 6.2.1 Global GLP-1 Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global GLP-1 Drug Sales by Application (2021-2032) & (Sales (k PMT))
  8. 6.2.3 Global GLP-1 Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global GLP-1 Drug Price by Application
7 Company Profiles
  1. 7.1 Novo Nordisk
  2. 7.1.1 Novo Nordisk Company Information
  3. 7.1.2 Novo Nordisk Business Overview
  4. 7.1.3 Novo Nordisk GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novo Nordisk GLP-1 Drug Product Portfolio
  6. 7.1.5 Novo Nordisk Recent Developments
  7. 7.2 Eli Lilly
  8. 7.2.1 Eli Lilly Company Information
  9. 7.2.2 Eli Lilly Business Overview
  10. 7.2.3 Eli Lilly GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly GLP-1 Drug Product Portfolio
  12. 7.2.5 Eli Lilly Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi GLP-1 Drug Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Teva
  20. 7.4.1 Teva Company Information
  21. 7.4.2 Teva Business Overview
  22. 7.4.3 Teva GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Teva GLP-1 Drug Product Portfolio
  24. 7.4.5 Teva Recent Developments
  25. 7.5 Jiangsu Hansoh Pharmaceutical
  26. 7.5.1 Jiangsu Hansoh Pharmaceutical Company Information
  27. 7.5.2 Jiangsu Hansoh Pharmaceutical Business Overview
  28. 7.5.3 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Jiangsu Hansoh Pharmaceutical GLP-1 Drug Product Portfolio
  30. 7.5.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  31. 7.6 Huadong Medicine
  32. 7.6.1 Huadong Medicine Company Information
  33. 7.6.2 Huadong Medicine Business Overview
  34. 7.6.3 Huadong Medicine GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Huadong Medicine GLP-1 Drug Product Portfolio
  36. 7.6.5 Huadong Medicine Recent Developments
  37. 7.7 Benemae Pharmaceutical
  38. 7.7.1 Benemae Pharmaceutical Company Information
  39. 7.7.2 Benemae Pharmaceutical Business Overview
  40. 7.7.3 Benemae Pharmaceutical GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Benemae Pharmaceutical GLP-1 Drug Product Portfolio
  42. 7.7.5 Benemae Pharmaceutical Recent Developments
  43. 7.8 Tonghua Dongbao Pharma
  44. 7.8.1 Tonghua Dongbao Pharma Company Information
  45. 7.8.2 Tonghua Dongbao Pharma Business Overview
  46. 7.8.3 Tonghua Dongbao Pharma GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Tonghua Dongbao Pharma GLP-1 Drug Product Portfolio
  48. 7.8.5 Tonghua Dongbao Pharma Recent Developments
  49. 7.9 Chia Tai-Tianqing Pharmaceutical
  50. 7.9.1 Chia Tai-Tianqing Pharmaceutical Company Information
  51. 7.9.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  52. 7.9.3 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Chia Tai-Tianqing Pharmaceutical GLP-1 Drug Product Portfolio
  54. 7.9.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca GLP-1 Drug Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America GLP-1 Drug Market Size by Type
  2. 8.1.1 North America GLP-1 Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America GLP-1 Drug Sales by Type (2021-2032)
  4. 8.1.3 North America GLP-1 Drug Price by Type (2021-2032)
  5. 8.2 North America GLP-1 Drug Market Size by Indications
  6. 8.2.1 North America GLP-1 Drug Revenue by Indications (2021-2032)
  7. 8.2.2 North America GLP-1 Drug Sales by Indications (2021-2032)
  8. 8.2.3 North America GLP-1 Drug Price by Indications (2021-2032)
  9. 8.3 North America GLP-1 Drug Market Size by Country
  10. 8.3.1 North America GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America GLP-1 Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe GLP-1 Drug Market Size by Type
  2. 9.1.1 Europe GLP-1 Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe GLP-1 Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe GLP-1 Drug Price by Type (2021-2032)
  5. 9.2 Europe GLP-1 Drug Market Size by Indications
  6. 9.2.1 Europe GLP-1 Drug Revenue by Indications (2021-2032)
  7. 9.2.2 Europe GLP-1 Drug Sales by Indications (2021-2032)
  8. 9.2.3 Europe GLP-1 Drug Price by Indications (2021-2032)
  9. 9.3 Europe GLP-1 Drug Market Size by Country
  10. 9.3.1 Europe GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe GLP-1 Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China GLP-1 Drug Market Size by Type
  2. 10.1.1 China GLP-1 Drug Revenue by Type (2021-2032)
  3. 10.1.2 China GLP-1 Drug Sales by Type (2021-2032)
  4. 10.1.3 China GLP-1 Drug Price by Type (2021-2032)
  5. 10.2 China GLP-1 Drug Market Size by Indications
  6. 10.2.1 China GLP-1 Drug Revenue by Indications (2021-2032)
  7. 10.2.2 China GLP-1 Drug Sales by Indications (2021-2032)
  8. 10.2.3 China GLP-1 Drug Price by Indications (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia GLP-1 Drug Market Size by Type
  2. 11.1.1 Asia GLP-1 Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia GLP-1 Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia GLP-1 Drug Price by Type (2021-2032)
  5. 11.2 Asia GLP-1 Drug Market Size by Indications
  6. 11.2.1 Asia GLP-1 Drug Revenue by Indications (2021-2032)
  7. 11.2.2 Asia GLP-1 Drug Sales by Indications (2021-2032)
  8. 11.2.3 Asia GLP-1 Drug Price by Indications (2021-2032)
  9. 11.3 Asia GLP-1 Drug Market Size by Country
  10. 11.3.1 Asia GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia GLP-1 Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA GLP-1 Drug Market Size by Type
  2. 12.1.1 SAMEA GLP-1 Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA GLP-1 Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA GLP-1 Drug Price by Type (2021-2032)
  5. 12.2 SAMEA GLP-1 Drug Market Size by Indications
  6. 12.2.1 SAMEA GLP-1 Drug Revenue by Indications (2021-2032)
  7. 12.2.2 SAMEA GLP-1 Drug Sales by Indications (2021-2032)
  8. 12.2.3 SAMEA GLP-1 Drug Price by Indications (2021-2032)
  9. 12.3 SAMEA GLP-1 Drug Market Size by Country
  10. 12.3.1 SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA GLP-1 Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 GLP-1 Drug Value Chain Analysis
  2. 13.1.1 GLP-1 Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 GLP-1 Drug Production Mode & Process
  6. 13.2 GLP-1 Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 GLP-1 Drug Distributors
  9. 13.2.3 GLP-1 Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst